Stryker Corp
Exchange: NYSESector: HealthcareIndustry: Medical Devices
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually.
Did you know?
Trading 38% above its estimated fair value of $206.96.
Current Price
$331.54
+0.65%GoodMoat Value
$206.96
37.6% overvaluedProfile
Valuation (TTM)
Market Cap$126.79B
P/E39.06
EV$138.95B
P/B5.66
Shares Out382.42M
P/Sales5.05
Revenue$25.12B
EV/EBITDA24.82
Stryker Corp (SYK) Stock Analysis
Market Cap$126.79B
Current Price$331.54
P/E Ratio39.06
Forward P/E—
PEG Ratio0.72
EPS$8.40
Book Value$58.63
P/B Ratio5.66
SYK Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 18.6% FCF growth (CAGR)
Cash vs Debt
Net Debt: 11.8B
Revenue
14.9B
FY19
14.4B
FY20
17.1B
FY21
18.4B
FY22
20.5B
FY23
22.6B
FY24
25.1B
FY25
Net Income
2.1B
FY19
1.6B
FY20
2.0B
FY21
2.4B
FY22
3.2B
FY23
3.0B
FY24
3.2B
FY25
SYK 52-Week Range
$325.23
$400.54
50-Day MA: $356.50200-Day MA: $368.37
Did you know?
Earnings per share grew at a 18.6% CAGR.
Stryker Corp (SYK) Financial Summary
Stryker Corp (SYK) is a Healthcare company in the Medical Devices industry, listed on NYSE. The stock currently trades at $331.54 with a market capitalization of $126.79B.
Key valuation metrics include a P/E ratio of 39.06, price-to-book ratio of 5.66, and EPS of $8.40. The company reports a profit margin of 12.9% and return on equity of 14.5%.
SYK Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $126.79B |
| P/E Ratio | 39.06 |
| EPS | $8.40 |
| P/B Ratio | 5.66 |
| P/S Ratio | 5.05 |
| EV/EBITDA | 24.82 |
| Dividend Yield | 1.01% |
| Profit Margin | 12.9% |
| Return on Equity | 14.5% |
| Debt/Equity | 0.71 |
SYK Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $14.88B | $2.08B |
| FY20 | $14.35B | $1.60B |
| FY21 | $17.11B | $1.99B |
| FY22 | $18.45B | $2.36B |
| FY23 | $20.50B | $3.17B |
| FY24 | $22.59B | $2.99B |
| FY25 | $25.12B | $3.25B |
Stryker Corp (SYK) Valuation
Based on GoodMoat's DCF model, Stryker Corp has a fair value estimate of $206.96. At the current price of $331.54, the stock appears 60.2% overvalued relative to our intrinsic value estimate.
SYK Quality Indicators
Stryker Corp maintains a profit margin of 12.9% and an operating margin of 19.5%. Return on equity stands at 14.5%. The current ratio is 1.89. Debt-to-equity ratio is 0.71.
About Stryker Corp
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually.
SYK Free Cash Flow
Stryker Corp generated $4.28B in trailing twelve-month free cash flow, representing an FCF yield of 3.38%. This moderate FCF yield indicates reasonable cash generation.
SYK Shares Outstanding
Stryker Corp has 0.38 billion shares outstanding at a share price of $331.54, giving it a market capitalization of $126.79B.
SYK Recent Insider Trades
Recent insider transactions at Stryker Corp include:
| Insider | Type | Shares | Value |
|---|---|---|---|
| STRYKER RONDA E | SELL | 14,437 | $5.18M |
| Pierce James Andrew (Group President) | SELL | 475 | $175214.68 |